

Harry Dolstra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4310290/publications.pdf>

Version: 2024-02-01

119
papers

5,800
citations

66343

42
h-index

88630

70
g-index

127
all docs

127
docs citations

127
times ranked

7612
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----------|
| 1 | Induction of myelodysplasia by myeloid-derived suppressor cells. <i>Journal of Clinical Investigation</i> , 2013, 123, 4595-4611. | 8.2 | 254 |
| 2 | Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. <i>Bone Marrow Transplantation</i> , 2021, 56, 1651-1664. | 2.4 | 221 |
| 3 | A Human Minor Histocompatibility Antigen Specific for B Cell Acute Lymphoblastic Leukemia. <i>Journal of Experimental Medicine</i> , 1999, 189, 301-308. | 8.5 | 207 |
| 4 | Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process. <i>PLoS ONE</i> , 2011, 6, e20740. | 2.5 | 199 |
| 5 | Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. <i>Cancer Research</i> , 2015, 75, 2928-2936. | 0.9 | 193 |
| 6 | The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. <i>Bone Marrow Transplantation</i> , 2020, 55, 2071-2076. | 2.4 | 163 |
| 7 | High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy. <i>PLoS ONE</i> , 2010, 5, e9221. | 2.5 | 150 |
| 8 | The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-Ts come into focus. <i>Bone Marrow Transplantation</i> , 2020, 55, 1604-1613. | 2.4 | 147 |
| 9 | A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2005, 115, 3506-3516. | 8.2 | 142 |
| 10 | PD-1/PD-L1 Interactions Contribute to Functional T-Cell Impairment in Patients Who Relapse with Cancer After Allogeneic Stem Cell Transplantation. <i>Cancer Research</i> , 2011, 71, 5111-5122. | 0.9 | 140 |
| 11 | Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients. <i>Clinical Cancer Research</i> , 2017, 23, 4107-4118. | 7.0 | 139 |
| 12 | siRNA silencing of PD-L1 and PD-L2 on dendritic cells augments expansion and function of minor histocompatibility antigen-specific CD8+ T cells. <i>Blood</i> , 2010, 116, 4501-4511. | 1.4 | 133 |
| 13 | Comprehensive Phenotyping of T Cells Using Flow Cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 647-654. | 1.5 | 133 |
| 14 | Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. <i>Bone Marrow Transplantation</i> , 2022, 57, 1217-1239. | 2.4 | 119 |
| 15 | Single-cell analysis reveals that stochasticity and paracrine signaling control interferon-alpha production by plasmacytoid dendritic cells. <i>Nature Communications</i> , 2018, 9, 3317. | 12.8 | 116 |
| 16 | Improving dendritic cell vaccine immunogenicity by silencing PD-1 ligands using siRNA-lipid nanoparticles combined with antigen mRNA electroporation. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 285-297. | 4.2 | 111 |
| 17 | Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. <i>Blood</i> , 2014, 124, 3490-3500. | 1.4 | 103 |
| 18 | Cytotoxic T cells are able to efficiently eliminate cancer cells by additive cytotoxicity. <i>Nature Communications</i> , 2021, 12, 5217. | 12.8 | 99 |

| # | ARTICLE | IF | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Multicenter Analyses Demonstrate Significant Clinical Effects of Minor Histocompatibility Antigens on GvHD and GvL after HLA-Matched Related and Unrelated Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1244-1253. | 2.0 | 93 |
| 20 | Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms. <i>Leukemia</i> , 2003, 17, 621-629. | 7.2 | 80 |
| 21 | Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. <i>International Journal of Cancer</i> , 2008, 123, 2354-2361. | 5.1 | 76 |
| 22 | Natural Killer Cells Generated from Cord Blood Hematopoietic Progenitor Cells Efficiently Target Bone Marrow-Residing Human Leukemia Cells in NOD/SCID/IL2R γ null Mice. <i>PLoS ONE</i> , 2013, 8, e64384. | 2.5 | 71 |
| 23 | Recognition of a B cell leukemia-associated minor histocompatibility antigen by CTL. <i>Journal of Immunology</i> , 1997, 158, 560-5. | 0.8 | 71 |
| 24 | Defining Early Human NK Cell Developmental Stages in Primary and Secondary Lymphoid Tissues. <i>PLoS ONE</i> , 2012, 7, e30930. | 2.5 | 69 |
| 25 | Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention. <i>Blood</i> , 2012, 120, 728-736. | 1.4 | 69 |
| 26 | Phenotype Frequencies of Autosomal Minor Histocompatibility Antigens Display Significant Differences among Populations. <i>PLoS Genetics</i> , 2007, 3, e103. | 3.5 | 68 |
| 27 | Association of MicroRNA-18 Expression With Altered Frequency and Activation of Plasmacytoid Dendritic Cells in Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1891-1902. | 5.6 | 67 |
| 28 | Peptide-mediated delivery of therapeutic mRNA in ovarian cancer. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 141, 180-190. | 4.3 | 62 |
| 29 | Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1381-1392. | 4.2 | 61 |
| 30 | Expansion of CD8 ⁺ CD57 ⁺ T cells after allogeneic BMT is related with a low incidence of relapse and with cytomegalovirus infection. <i>British Journal of Haematology</i> , 1995, 90, 300-307. | 2.5 | 60 |
| 31 | B and T Lymphocyte Attenuator Mediates Inhibition of Tumor-Reactive CD8 ⁺ T Cells in Patients After Allogeneic Stem Cell Transplantation. <i>Journal of Immunology</i> , 2012, 189, 39-49. | 0.8 | 60 |
| 32 | Toward targeting B cell cancers with CD4 ⁺ CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis. <i>Journal of Experimental Medicine</i> , 2008, 205, 2863-2872. | 8.5 | 59 |
| 33 | NOD2 polymorphisms predict severe acute graft-versus-host and treatment-related mortality in T-cell-depleted haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2009, 44, 243-248. | 2.4 | 57 |
| 34 | A trispesific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. <i>Leukemia</i> , 2021, 35, 1586-1596. | 7.2 | 57 |
| 35 | Bi-directional allelic recognition of the human minor histocompatibility antigen HB-1 by cytotoxic T lymphocytes. <i>European Journal of Immunology</i> , 2002, 32, 2748-2758. | 2.9 | 55 |
| 36 | The Aryl Hydrocarbon Receptor Antagonist StemRegenin 1 Promotes Human Plasmacytoid and Myeloid Dendritic Cell Development from CD34 ⁺ Hematopoietic Progenitor Cells. <i>Stem Cells and Development</i> , 2014, 23, 955-967. | 2.1 | 53 |

| # | ARTICLE | IF | CITATIONS |
|----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | TCR β cytotoxic T lymphocytes expressing the killer cell-inhibitory receptor p58.2 (CD158b) selectively lyse acute myeloid leukemia cells. <i>Bone Marrow Transplantation</i> , 2001, 27, 1087-1093. | 2.4 | 51 |
| 38 | Umbilical cord blood CD34 ⁺ progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rg ^{-/-} mice. <i>Oncolmmunology</i> , 2017, 6, e1320630. | 4.6 | 50 |
| 39 | TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer. <i>Oncolmmunology</i> , 2020, 9, 1843247. | 4.6 | 48 |
| 40 | Myeloid leukemic progenitor cells can be specifically targeted by minor histocompatibility antigen LRH-1-reactive cytotoxic T cells. <i>Blood</i> , 2009, 113, 2312-2323. | 1.4 | 46 |
| 41 | Increased Coexpression of PD-1, TIGIT, and KLRG-1 on Tumor-Reactive CD8+ T Cells During Relapse after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 666-677. | 2.0 | 45 |
| 42 | Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. <i>Bone Marrow Transplantation</i> , 2022, 57, 742-752. | 2.4 | 45 |
| 43 | Combined IL-15 and IL-12 drives the generation of CD34 ⁺ -derived natural killer cells with superior maturation and alloreactivity potential following adoptive transfer. <i>Oncolmmunology</i> , 2015, 4, e1017701. | 4.6 | 44 |
| 44 | CXCR4, but not CXCR3, drives CD8 ⁺ T cell entry into and migration through the murine bone marrow. <i>European Journal of Immunology</i> , 2019, 49, 576-589. | 2.9 | 44 |
| 45 | Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients. <i>Oncotarget</i> , 2018, 9, 34810-34820. | 1.8 | 44 |
| 46 | Association of Disparities in Known Minor Histocompatibility Antigens with Relapse-Free Survival and Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 274-282. | 2.0 | 43 |
| 47 | CLEC12A-Mediated Antigen Uptake and Cross-Presentation by Human Dendritic Cell Subsets Efficiently Boost Tumor-Reactive T Cell Responses. <i>Journal of Immunology</i> , 2016, 197, 2715-2725. | 0.8 | 43 |
| 48 | MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 721-733. | 3.1 | 43 |
| 49 | Harnessing natural killer cells for the treatment of ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 157, 810-816. | 1.4 | 43 |
| 50 | siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8+ T cells in NOD/SCID/IL2Rg ^{-/-} mice. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 645-654. | 4.2 | 42 |
| 51 | Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1000-1008. | 2.0 | 42 |
| 52 | Immune checkpoint molecules in acute myeloid leukaemia: managing the double-edged sword. <i>British Journal of Haematology</i> , 2018, 181, 38-53. | 2.5 | 42 |
| 53 | Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy. <i>Oncolmmunology</i> , 2018, 7, e1488565. | 4.6 | 41 |
| 54 | Decitabine enhances targeting of AML cells by CD34+ progenitor-derived NK cells in NOD/SCID/IL2Rg ^{-/-} mice. <i>Blood</i> , 2018, 131, 202-214. | 1.4 | 40 |

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 55 | Expression of C-IAP1, C-IAP2 and SURVIVIN discriminates different types of lymphoid malignancies. <i>British Journal of Haematology</i> , 2005, 130, 852-859. | 2.5 | 39 |
| 56 | Decreased Levels of Circulating IL17-Producing CD161+CCR6+ T Cells Are Associated with Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation. <i>PLoS ONE</i> , 2012, 7, e50896. | 2.5 | 39 |
| 57 | Efficient Nontoxic Delivery of PD-L1 and PD-L2 siRNA Into Dendritic Cell Vaccines Using the Cationic Lipid SAINT-18. <i>Journal of Immunotherapy</i> , 2015, 38, 145-154. | 2.4 | 39 |
| 58 | Targeting the IL17 Pathway for the Prevention of Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 752-759. | 2.0 | 36 |
| 59 | Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion. <i>Cancer Immunology Research</i> , 2017, 5, 710-715. | 3.4 | 36 |
| 60 | Expression of P2X5 in lymphoid malignancies results in LRH-1-specific cytotoxic T-cell-mediated lysis. <i>British Journal of Haematology</i> , 2008, 141, 799-807. | 2.5 | 33 |
| 61 | Monochlorobimane Does Not Selectively Label Glutathione in Peripheral Blood Mononuclear Cells. <i>Analytical Biochemistry</i> , 1994, 217, 41-47. | 2.4 | 32 |
| 62 | A Phase I Study of Allogeneic Natural Killer Cell Therapy Generated from Cord Blood Hematopoietic Stem and Progenitor Cells in Elderly Acute Myeloid Leukemia Patients. <i>Blood</i> , 2015, 126, 1357-1357. | 1.4 | 31 |
| 63 | An alternatively spliced CXCL16 isoform expressed by dendritic cells is a secreted chemoattractant for CXCR6+ cells. <i>Journal of Leukocyte Biology</i> , 2010, 87, 1029-1039. | 3.3 | 29 |
| 64 | Natural Killer Cell Differentiation from Hematopoietic Stem Cells: A Comparative Analysis of Heparin- and Stromal Cellâ€‘Supported Methods. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 536-545. | 2.0 | 29 |
| 65 | The Aryl Hydrocarbon Receptor Antagonist StemRegenin1 Improves In Vitro Generation of Highly Functional Natural Killer Cells from CD34⁺ Hematopoietic Stem and Progenitor Cells. <i>Stem Cells and Development</i> , 2015, 24, 2886-2898. | 2.1 | 29 |
| 66 | PD-L1 microSPECT/CT Imaging for Longitudinal Monitoring of PD-L1 Expression in Syngeneic and Humanized Mouse Models for Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 150-161. | 3.4 | 29 |
| 67 | What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings. <i>Cytotherapy</i> , 2020, 22, 388-397. | 0.7 | 29 |
| 68 | Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 712-719. | 2.0 | 28 |
| 69 | IL-15 superagonist N-803 improves IFNÎ³ production and killing of leukemia and ovarian cancer cells by CD34+â€‘progenitor-derived NK cells. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1305-1321. | 4.2 | 27 |
| 70 | CD3+/CD19+-depleted grafts in HLA-matched allogeneic peripheral blood stem cell transplantation lead to early NK cell cytolytic responses and reduced inhibitory activity of NKG2A. <i>Leukemia</i> , 2010, 24, 583-591. | 7.2 | 26 |
| 71 | Ex Vivo Generated Natural Killer Cells Acquire Typical Natural Killer Receptors and Display a Cytotoxic Gene Expression Profile Similar to Peripheral Blood Natural Killer Cells. <i>Stem Cells and Development</i> , 2012, 21, 2926-2938. | 2.1 | 26 |
| 72 | A Polymorphism in the Splice Donor Site of ZNF419 Results in the Novel Renal Cell Carcinoma-Associated Minor Histocompatibility Antigen ZAPHIR. <i>PLoS ONE</i> , 2011, 6, e21699. | 2.5 | 24 |

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 73 | Multiple myeloma patients receiving pre-emptive donor lymphocyte infusion after partial T-cell-depleted allogeneic stem cell transplantation show a long progression-free survival. <i>Bone Marrow Transplantation</i> , 2007, 40, 355-359. | 2.4 | 23 |
| 74 | The magnitude of cytokine production by stimulated CD56+ cells is associated with early stages of systemic sclerosis. <i>Clinical Immunology</i> , 2016, 173, 76-80. | 3.2 | 23 |
| 75 | Reprogramming of bone marrow myeloid progenitor cells in patients with severe coronary artery disease. <i>ELife</i> , 2020, 9, . | 6.0 | 23 |
| 76 | Partial T Cell-Depleted Allogeneic Stem Cell Transplantation following Reduced-Intensity Conditioning Creates a Platform for Immunotherapy with Donor Lymphocyte Infusion and Recipient Dendritic Cell Vaccination in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 320-332. | 2.0 | 22 |
| 77 | Umbilical cord blood-derived cellular products for cancer immunotherapy. <i>Cytotherapy</i> , 2015, 17, 739-748. | 0.7 | 22 |
| 78 | Quantification of donor and recipient hemopoietic cells by real-time PCR of single nucleotide polymorphisms. <i>Leukemia</i> , 2003, 17, 630-633. | 7.2 | 21 |
| 79 | Cellular adoptive immunotherapy after allogeneic stem cell transplantation. <i>Current Opinion in Oncology</i> , 2005, 17, 617-621. | 2.4 | 21 |
| 80 | A phase I/II minor histocompatibility antigen-loaded dendritic cell vaccination trial to safely improve the efficacy of donor lymphocyte infusions in myeloma. <i>Bone Marrow Transplantation</i> , 2017, 52, 1378-1383. | 2.4 | 21 |
| 81 | Hematopoietic stem cell-derived myeloid and plasmacytoid DC-based vaccines are highly potent inducers of tumor-reactive T cell and NK cell responses <i>ex vivo</i> . <i>OncImmunology</i> , 2017, 6, e1285991. | 4.6 | 20 |
| 82 | Intraperitoneal infusion of ex vivo-cultured allogeneic NK cells in recurrent ovarian carcinoma patients (a phase I study). <i>Medicine (United States)</i> , 2019, 98, e14290. | 1.0 | 20 |
| 83 | The impact of circulating suppressor cells in multiple myeloma patients on clinical outcome of DLIs. <i>Bone Marrow Transplantation</i> , 2015, 50, 822-828. | 2.4 | 17 |
| 84 | Dynamics in chimerism of T cells and dendritic cells in relapsed CML patients and the influence on the induction of alloreactivity following donor lymphocyte infusion. <i>Bone Marrow Transplantation</i> , 2007, 40, 585-592. | 2.4 | 16 |
| 85 | Aberrant expression of the hematopoietic-restricted minor histocompatibility antigen LRH-1 on solid tumors results in efficient cytotoxic T cell-mediated lysis. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 429-439. | 4.2 | 15 |
| 86 | Polymorphisms in CCR6 Are Associated with Chronic Graft-versus-Host Disease and Invasive Fungal Disease in Matched-Related Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1443-1449. | 2.0 | 15 |
| 87 | T cells expressing the activating NK-cell receptors KIR2DS4, NKG2C and NKG2D are elevated in paroxysmal nocturnal hemoglobinuria and cytotoxic toward hematopoietic progenitor cell lines. <i>Experimental Hematology</i> , 2011, 39, 751-762.e3. | 0.4 | 15 |
| 88 | Generation of autologous cytotoxic and helper T-cell responses against the B-cell leukemia-associated antigen HB-1: relevance for precursor B-ALL-specific immunotherapy. <i>Blood</i> , 2003, 102, 2885-2891. | 1.4 | 14 |
| 89 | LB-ARHGDI1B-1R as a novel minor histocompatibility antigen for therapeutic application. <i>Haematologica</i> , 2015, 100, e419-e422. | 3.5 | 14 |
| 90 | Human CD34+ Myeloid Leukemic Progenitor Cells Are Susceptible to Lysis by Minor Histocompatibility Antigen LRH-1-Specific Cytotoxic T Lymphocytes. <i>Blood</i> , 2006, 108, 134-134. | 1.4 | 14 |

| # | ARTICLE | IF | CITATIONS |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 91 | Efficient Activation of LRH-1 ⁺ -specific CD8 ⁺ T-cell Responses From Transplanted Leukemia Patients by Stimulation With P2X5 mRNA-electroporated Dendritic Cells. <i>Journal of Immunotherapy</i> , 2009, 32, 539-551. | 2.4 | 13 |
| 92 | Clinically applicable CD34 ⁺ -derived blood dendritic cell subsets exhibit key subset-specific features and potently boost anti-tumor T and NK cell responses. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 3167-3181. | 4.2 | 13 |
| 93 | CD34 ⁺ progenitor-derived NK cell and gemcitabine combination therapy increases killing of ovarian cancer cells in NOD/SCID/IL2Rg ^{-/-} mice. <i>Oncolmunology</i> , 2021, 10, 1981049. | 4.6 | 13 |
| 94 | PD-L1 siRNA-mediated silencing in acute myeloid leukemia enhances anti-leukemic T cell reactivity. <i>Bone Marrow Transplantation</i> , 2020, 55, 2308-2318. | 2.4 | 12 |
| 95 | Biodistribution and Retention Time of Retrovirally Labeled T Lymphocytes in Mice is Strongly Influenced by the Culture Period Before Infusion. <i>Journal of Immunotherapy</i> , 2002, 25, 385-395. | 2.4 | 10 |
| 96 | Homing Characteristics of Donor T Cells after Experimental Allogeneic Bone Marrow Transplantation and Posttransplantation Therapy for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 378-386. | 2.0 | 10 |
| 97 | Ex Vivo Generation of Interstitial and Langerhans Cell-like Dendritic Cell Subset ⁺ -based Vaccines for Hematological Malignancies. <i>Journal of Immunotherapy</i> , 2014, 37, 267-277. | 2.4 | 9 |
| 98 | CD16-IL15-CLEC12A Trispecific Killer Engager (TriKE) Drives NK Cell Expansion, Activation, and Antigen Specific Killing of Cancer Stem Cells in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1454-1454. | 1.4 | 8 |
| 99 | Immunotherapeutic approaches to treat multiple myeloma. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 896-910. | 3.3 | 7 |
| 100 | Concurrent Detection of Circulating Minor Histocompatibility Antigen-Specific CD8 ⁺ T Cells in SCT Recipients by Combinatorial Encoding MHC Multimers. <i>PLoS ONE</i> , 2011, 6, e21266. | 2.5 | 6 |
| 101 | Monitoring of Developing Graft-Versus-Host Disease Mediated by Herpes Simplex Virus Thymidine Kinase Gene-Transduced T Cells. <i>Human Gene Therapy</i> , 2003, 14, 341-351. | 2.7 | 5 |
| 102 | Induction of multiple myeloma-reactive T cells during post-transplantation immunotherapy with donor lymphocytes and recipient DCs. <i>Bone Marrow Transplantation</i> , 2012, 47, 1229-1234. | 2.4 | 5 |
| 103 | Cell composition and expansion strategy can reduce the beneficial effect of AKT-inhibition on functionality of CD8 ⁺ T cells. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2259-2273. | 4.2 | 4 |
| 104 | Time toAkt. <i>Oncolmunology</i> , 2015, 4, e1003016. | 4.6 | 3 |
| 105 | Functionally active NKG2A-expressing natural killer cells are elevated in rheumatoid arthritis patients compared to psoriatic arthritis patients and healthy donors. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 795-804. | 0.8 | 3 |
| 106 | Refinement of molecular approaches to improve the chance of identification of hematopoietic-restricted minor histocompatibility antigens. <i>Journal of Immunological Methods</i> , 2008, 329, 125-137. | 1.4 | 2 |
| 107 | The first steps towards a diverse and inclusive EBMT: a position paper. <i>Bone Marrow Transplantation</i> , 2022, 57, 343-346. | 2.4 | 2 |
| 108 | Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands. <i>Frontiers in Immunology</i> , 2022, 13, 734256. | 4.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 109 | Gender influences the birth order effect in HLA-identical stem cell transplantation. Blood, 2013, 121, 4809-4811. | 1.4 | 1 |
| 110 | Use of RNA Electroporated DC for Activation of LRH-1 Specific Cytotoxic T Lymphocytes in the Treatment of Lymphoid Malignancies.. Blood, 2006, 108, 138-138. | 1.4 | 1 |
| 111 | The Aryl Hydrocarbon Receptor Antagonist Stemregenin 1 Stimulates Expression of NK Cell Related Transcription Factors, Thereby It Facilitates Generation of Highly Functional NK Cells in Vitro. Blood, 2014, 124, 3833-3833. | 1.4 | 1 |
| 112 | Extensive natural killer cell receptor phenotyping on NK and T cells discloses differences in RA and PsA, potentially mirroring diverse immunoregulatory functions. Journal of Translational Medicine, 2011, 9, P42. | 4.4 | 0 |
| 113 | A Novel Tissue-Restricted Minor Histocompatibility Antigen Resulting from Differential Expression Due to a Deletion/Insertion Polymorphism in the P2X5 Purinergic Receptor Gene.. Blood, 2004, 104, 3062-3062. | 1.4 | 0 |
| 114 | The Balance in Chimerism between T Cells and Blood Dendritic Cells in Relapsed CML Patients Influences the Induction of Alloreactivity Following Donor Lymphocyte Infusion.. Blood, 2006, 108, 5139-5139. | 1.4 | 0 |
| 115 | Vaccination with Host Dendritic Cells Induces Graft-Versus-Leukemia Responses without Severe Graft-Versus-Host Disease in a Preclinical Mouse Model for Allogeneic Stem Cell Transplantation.. Blood, 2006, 108, 3239-3239. | 1.4 | 0 |
| 116 | Aberrant Expression in Human Epithelial Cancers of the P2X5-Encoded Minor Histocompatibility Antigen LRH-1: Implications for Graft-Versus-Tumor Immunity Against Solid Tumors.. Blood, 2007, 110, 1795-1795. | 1.4 | 0 |
| 117 | Ex vivo Human Antigen-specific T Cell Proliferation and Degranulation. Bio-protocol, 2012, 2, . | 0.4 | 0 |
| 118 | Akt Signalling Inhibition Promotes The Ex Vivo generation Of Minor Histocompatibility Antigen-Specific CD8+ Memory Stem T Cells. Blood, 2013, 122, 3269-3269. | 1.4 | 0 |
| 119 | Role of Co-inhibitory Molecules in Tumor Escape from CTL Attack. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 31-58. | 0.1 | 0 |